Document:

Exhibit 10.157

 

 

Mr. Martin D. Brew

6838 South Bluff Court

Gainesville, GA 30506

 

Via EMAIL: martybrew@bellsouth.net

 

RE: Senior Vice President, Chief Financial Officer and Treasurer of AdCare Health Systems, Inc.

 

Dear Marty,

 

I am pleased to offer you the position of Senior Vice President, Chief Financial Officer and Treasurer of AdCare Health Systems, Inc. As we discussed, initially when you join us effective May 17, 2011 you will have the title of Senior Vice President; when the Board of Directors next convenes on June 3, 2011 you will be elected to the additional positions of Chief Financial Officer and Treasurer.

 

Set forth below are the some of the specifics of our offer and AdCare’s policies as they pertain to executive employees:

 

1.             You will be paid an annual salary of $175,000. You will be eligible for an increase in salary of $25,000 or more no later than your first employment anniversary based on your work performance.

 

2.             You will be eligible to participate in an incentive compensation program with a target of 75% of your base annual salary (i.e. $131,000 for 2011) with specified goals that will be the same as set for the CEO. Any incentive compensation awarded will be prorated during your first year of service and will be subject to all provisions of AdCare’s incentive compensation program.

 

3.             You will receive an initial grant of 50,000 stock options vesting over three years and eligible for future grants under AdCare’s Option Plan detailed in the current proxy to be voted on at the AdCare annual meeting on June 3, 2011 or warrants with similar features should AdCare’s shareholders not approve the Option Plan.

 

4.             You will be eligible to participate in AdCare’s executive expense allowance program and will be reimbursed $15,000 on an annual basis for expenses incurred in connection with performing duties for the Company.

 

5.             You will be eligible to participate in all benefit programs made available to AdCare employees including, but not limited to health care, vacation, flexible spending accounts, 401(k) plan, etc. With respect to health care coverage, the Company will at its option either waive the waiting period required under its plan, or subsidize you under your COBRA plan such that your out- of-pocket expense does not exceed the employee payment required under our health care plan.

 

6.             Your employment will be “at will”, so that you may resign, or AdCare may terminate your employment at any time and for any reason whatsoever. If your employment is terminated by AdCare without cause during the first six months of your employment you will receive salary continuation for 3 months. If your employment is terminated by AdCare without cause during the second six months of your employment you will receive salary continuation for 6 months. If your employment is terminated by AdCare without cause after your first employment anniversary you will receive salary continuation for 12 months. If you are terminated by AdCare or an acquiring company due to a change in control event, you will receive salary continuation for two times these amounts (i.e.: if you are terminated without cause in connection with a change of control event during your first six months of service the salary continuation will be for six months). Salary continuation will be paid at the rate of your annual

 

 

Employment Offer

May 15, 2011

 

salary on the date of the without cause or change in control termination. You will be eligible for a formal employment contract that will further codify these arrangements on your first anniversary of employment.

 

7.           The Company will indemnify you for your actions and omissions associated with the performance of your responsibilities as Chief Financial Officer (not to include gross negligence or willful misconduct).  Additionally, you will be a covered officer under AdCare’s Director’s & Officer’s Insurance Policy a copy of which has been provided to you. Adcare agrees to continue to secure Director’s & Officer’s insurance coverage.

 

8.             You will report to AdCare’s President and Chief Executive Officer and will be located in AdCare’s Buckhead Office.

 

9.             You will be expected to execute AdCare’s Non-Competition Agreement as a condition of employment.

 

10.           You will be expected to cooperate and comply with all of AdCare’s background check and other pre and post employment policies and procedures.

 

If you have any questions or comments regarding any of the matters addressed in this letter, please feel free to contact me. If you accept AdCare’s employment offer and agree to the terms contained herein, please execute in the space provided below and email back a pdf countersigned copy to me at the e-address below. If we do not receive your acceptance before 5:00p.m., May 16, 2011 this offer will be rescinded.

 

We very much look forward to you joining the AdCare team and I personally look forward to a successful working relationship.

 

	
Sincerely,
    	
 
    
	
 
    	
 
    
	
/s/ Boyd P. Gentry
    	
 
    
	
Boyd P. Gentry
    	
 
    
	
Co-Chief Executive Officer
    	
 
    
	
AdCare Health Services, Inc.
    	
 
    
	
5057 Troy Road
    	
 
    
	
Springfield, Ohio 45502
    	
 
    
	
bpg@adcarehealth.com
    	
 
    
	
404.394.6596
    	
 
    
	
 
    	
 
    
	
ACKNOWLEDGED AND AGREED:
    	
 
    
	
 
    	
 
    
	
/s/ Martin D. Brew
    	
 
    
	
Martin D. Brew
    	
 
    
	
 
    	
 
    
	
cc:
    	
Dave Tenwick
    	
 
    
	
 
    	
Lynn Dombrosky
    	
 
    

 

2Exhibit 10.158

 

ADCARE HEALTH SYSTEMS, INC.

 

WARRANT

 

TO PURCHASE SHARES OF COMMON STOCK
 OF ADCARE HEALTH SYSTEMS, INC.

 

Dated as of January 10, 2011

 

 

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.  IT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS.

 

ADCARE HEALTH SYSTEMS, INC.

 

No. ASW185

 

WARRANT TO PURCHASE SHARES OF COMMON STOCK
 OF ADCARE HEALTH SYSTEMS, INC.

 

This Warrant, granted by the Board of Directors of AdCare Health Systems, Inc. as of January 10, 2011 (the “Grant Date”), certifies that, FOR VALUE RECEIVED, Boyd P. Gentry (the “Holder”), is entitled to purchase up to 250,000 voting common shares, no par value (the “Common Stock”), of AdCare Health Systems, Inc. (the “Company”) at a per share purchase price (the “Exercise Price”) of $4.13.  This Warrant is exercisable upon a vesting schedule and shall terminate and expire unless exercised on or before the tenth anniversary of the grant date. The shares of the Company’s Common Stock issuable upon the exercise of this Warrant are called herein the “Underlying Common Stock.”  The Holder may exercise this Warrant as to all or any portion of the shares of the Underlying Common Stock which it shall have the right to acquire hereunder.

 

(a)           Vesting Schedule.  Subject to the terms and conditions set forth herein, this Warrant shall vest with respect to one-third of the warrants upon issuance with the remaining warrants vesting equally over a period of two years provided that Holder has not ceased employment with the Company as of the date of vesting as set forth herein.  Except as otherwise provided herein, if the Holder ceases to be an employee of the Company, then no additional shares of Underlying Common Stock shall vest and the right to purchase such additional shares under this Warrant shall terminate.  Notwithstanding the foregoing, this Warrant shall vest and become immediately exercisable with respect to one hundred percent (100%) of the Underlying Common Stock if Company undergoes a Change in Control.  For purposes of this Warrant, a “Change in Control” shall be deemed to occur if Company executes an agreement providing for (i) the sale, conveyance, disposal, or encumbrance of all or substantially all of the Company’s assets or business; or (ii) the merger, reorganization, consolidation or any other transaction that results in the transfer of ownership of more than fifty percent (50%) of the Company’s Common Stock.

 

(b)           Exercise of Warrant.  In order to exercise all or any portion of this Warrant, the Holder must surrender for exercise this Warrant with the Purchase Form annexed hereto duly executed, together with payment in full of the Exercise Price then in effect for each share of Common Stock purchasable upon exercise of this Warrant.  Payment may be made (i) in cash or by certified or official bank check payable to the order of the Company

 

 

or by wire transfer of immediately available funds to an account designated by the Company for such purpose, (ii) without the payment of cash (a “Cashless Exercise”), by reducing the number of shares of Common Stock that would be obtainable upon the exercise of this Warrant and payment of the Exercise Price in cash so as to yield a number of shares of Common Stock upon the exercise of this Warrant equal to the product of (a) the number of shares of Common Stock for which this Warrant is exercisable as of the date of exercise (if the Exercise Price were being paid in cash) and (b) the Cashless Exercise Ratio, or (iii) a combination of (i) and (ii).  The date upon which the Holder exercises this Warrant is hereinafter referred to as the “Exercise Date”.

 

The “Cashless Exercise Ratio” shall equal a fraction, the numerator of which is the excess of the Current Market Value (as defined in Section (f)(v) hereof) per share of Common Stock on the Exercise Date over the Exercise Price per share as of the Exercise Date and the denominator of which is the Current Market Price per share of the Common Stock on the Exercise Date.  Upon surrender of this Warrant in connection with the Holder’s option to elect a Cashless Exercise, the number of shares of Common Stock deliverable upon a Cashless Exercise shall be equal to the number of shares of Common Stock issuable upon the exercise of Warrants that the Holder specifies are to be exercised pursuant to a Cashless Exercise multiplied by the Cashless Exercise Ratio.

 

If this Warrant should be exercised in part only, the Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant evidencing the right of the Holder to purchase the balance of the shares purchasable hereunder.  Upon receipt by the Company of this Warrant at the office of the Company, in proper form for exercise, accompanied by payment of the Exercise Price, the Holder shall be deemed to be the Holder of record of the shares of Common Stock issuable upon such exercise, notwithstanding that certificates representing such shares of Common Stock shall not then be actually delivered to the Holder.  If the stock transfer books of the Company shall be closed on the date of receipt of this Warrant and the Exercise Price as aforesaid, the Holder shall be deemed to be the Holder of such shares of Common Stock on the next succeeding day on which the stock transfer books of the Company shall be opened.

 

(c)           Reservation of Shares; Stock Fully Paid.  The Company agrees that at all times there shall be authorized and reserved for issuance upon exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance or delivery upon exercise of this Warrant.  All shares which may be issued upon exercise hereof will, upon issuance, be fully paid and nonassessable.  The Company shall pay all United States and state documentary stamp taxes, if any, in respect of the issue of the Common Stock.

 

(d)           Fractional Shares.  This Warrant shall be exercisable in such manner so as not to require the issuance of fractional shares of scrip representing fractional shares.  If, as a result of adjustment in the Underlying Common Stock or for any other reason, fractional shares would be issuable, no such fractional shares shall be issued.  In lieu thereof the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current market value of such fractional share.

 

2

 

(e)           Rights of the Holder.  The Holder shall not, by virtue hereof, be entitled to any rights of a shareholder in the Company, either at law or equity, and the rights of the Holder are limited to those expressed in the Warrant.

 

(f)            Adjustment of Exercise Rights.  The Exercise Price or the number of shares of Underlying Common Stock to be received upon the exercise of this Warrant, or both, shall be subject to adjustment from time to time as hereinafter in this Section (f) provides.

 

The Exercise Price shall be adjusted from time to time as follows:

 

(i)            In case the Company shall, at any time or from time to time while any of the Warrants are outstanding, (1) pay a dividend or make a distribution on its Common Stock in shares of Common Stock, (2) subdivide or split its outstanding shares of Common Stock, or (3) combine its outstanding Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior thereto shall be adjusted so that the holder of any Warrant thereafter surrendered for exercise shall be entitled to receive the number of shares of Common Stock or other securities of the Company which she would have owned or have been entitled to receive after the effectiveness of any of the events described above, had such Warrant been converted immediately prior to the effectiveness of such event.  An adjustment made pursuant to this subdivision (i) shall become effective, in the case of a dividend, on the payment date retroactively to immediately after the opening of business on the day following the record date for the determination of shareholders entitled to receive such dividend, and shall become effective in the case of a subdivision, split or combination immediately after the opening of business on the day following the day when such subdivision or combination, as the case may be, becomes effective.

 

(ii)           In case the Company shall, at any time or from time to time while any of the Warrants are outstanding, issue Common Stock, convertible securities (convertible or exercisable into Common Stock) or debentures (except debentures issued simultaneously with the Warrants) to subscribe for or purchase shares of Common Stock at a price per share less than the Exercise Price then in effect at the record date mentioned below, the Exercise Price in effect immediately prior to the issuance of such Common Stock, convertible securities or debentures shall be adjusted as follows; provided, however, that if such issuance is in connection with the sale of such securities by the Company, such adjustment will be made only if the Warrant holder purchases her pro rata portion of the shares to be issued in such financing as provided in paragraph (vi) below.  The Exercise Price shall be multiplied by a fraction, of which the numerator shall be the number of shares of Common Stock outstanding immediately prior to such record date, plus the quotient determined by dividing the aggregate offering price of the total number of shares so offered by the Exercise Price, and of which the denominator shall be the number of shares of Common Stock outstanding immediately prior to such record date plus the number of additional shares of Common Stock offered for subscription or purchase.  Such adjustment shall become effective on the date of such issuance retroactively to immediately after the opening of business on the day following the record date for

 

3

 

the determination of shareholders entitled to receive such Common Stock, convertible securities or debentures.

 

(iii)          In case the Company shall, at any time or from time to time while any of the Warrants are outstanding, distribute to all holders of shares of its Common Stock evidences of its indebtedness or securities or assets (excluding cash dividends), the Exercise Price in effect immediately prior to such distribution shall be adjusted by multiplying the Exercise Price by a fraction, of which the numerator shall be the Current Market Price per share of the Common Stock on the record date mentioned below less than the then fair market value (as determined by the Board of Directors of the Corporation, whose determination shall be conclusive) of the portion of the assets or evidences of indebtedness distributed applicable to one share of Common Stock, and of which the denominator shall be such Current Market Price per share of Common Stock.  Such adjustment shall become effective on the date of such distribution retroactively to immediately after the opening of business on the day following the record date for the determination of shareholders entitled to receive such distribution.

 

(iv)          No adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least 1% of such price.

 

(v)           The “Current Market Price” at any date shall mean the price per share of Common Stock on such date determined by the Board of Directors as provided below.  The Current Market Price shall be the average of the daily closing prices per share of Common Stock for thirty (30) consecutive business days ending no more than fifteen (15) business days before the day in question (as adjusted for any stock dividend, split, combination or reclassification that took effect during such thirty (30) business day period).  The closing price for each day shall be the last reported sales price regular way or, in case no such reported sales take place on such day, the average of the last reported bid and asked prices regular way, in either case on the principal national securities exchange on which the Common Stock is listed or admitted to trading, or if not listed or admitted to trading on any national securities exchange, the average of the highest bid and the lowest asked prices quoted on the NYSE AMEX Equities (“AMEX”).  In the event that the Common Stock is not listed on a National Securities Exchange or traded on AMEX, but the shares are traded on the over-the-counter market, then the Current Market Price will mean the average of the last bid and asked prices for the Common Stock on the over-the-counter market.  If the Common Stock is not traded in such manner that the quotations referred to above are available for the period required hereunder, the Current Market Price per share of Common Stock shall be deemed to be fair value as determined by the Board of Directors (whose determination shall be conclusive), irrespective of any accounting treatment.

 

(vi)          (A) Notwithstanding the provisions of paragraph (ii) above, no future adjustments shall be made in the Exercise Price of any holder or transferee of such holder who does not purchase his or its pro rata portion of the shares to be issued in

 

4

 

future financings of the Company but only where the shares to be issued are offered so as to result in a reduction of the Exercise Price (a “Non-Participating Holder”).

 

(B) All of such Non-Participating Holder’s Warrants shall automatically and without further action on the part of such holder be converted into a like principal amount of a newly created series of warrants, which new warrants shall be identical in all respect to the Warrants, except that the Exercise Price of such series shall be fixed immediately prior to the subsequent financing and shall be subject to no further adjustments as provided herein.  The Board of Directors shall take all necessary actions to designate such new series.

 

(g)           Statement of Adjusted Exercise Price.  Whenever the Exercise Price of Underlying Common Stock are adjusted pursuant to Section (f), the Company shall forthwith prepare a written statement signed by the President or the Treasurer of the Company setting forth such adjustment. Such statement shall be filed among the permanent records of the Company and shall be delivered to the Holder.

 

(h)           Dissolution or Liquidation.  In case the Company shall liquidate or wind up its affairs, the Holder of this Warrant shall be entitled, upon the exercise thereof, to receive, in lieu of the Underlying Common Stock of the Company which he would have been entitled to receive, the same kind and amount of assets as would have been issued, distributed or paid to him upon any such dissolution, liquidations or winding up with respect to such shares of Common Stock of the Company, had he been the holder of record of such Underlying Common Stock on the record date for the determination of those entitled to receive any such liquidating distribution; provided, however, that all rights under this Warrant shall terminate on a date fixed by the Company, such date to be not earlier than the date of commencement of proceedings for dissolution, liquidation, or winding up and not later than 30 days after such commencement date, unless the Holder shall have, prior to such termination date, exercised this Warrant.  Notice of such termination of rights under this Warrants shall be given to the last registered Holder hereof, as the same shall appear on the books of the Company, by mail at least 30 days prior to such termination date.

 

(i)            Piggyback Registration Rights.  The Company hereby grants to the Holder piggyback registration rights with respect to all or any portion of the shares of Underlying Common Stock which Holder shall have the right to acquire hereunder.  In the event Company proposes to register any of its Common Stock or other securities under the Securities Act of 1933, as amended (the “Act”), in connection with the public offering of such securities, the Company shall, prior to the filing of any such registration, promptly give Holder written notice of such registration.  Upon the written request of Holder given within ten (10) days after receipt of such notice by the Company, the Company shall cause to be registered under the Act any of the Underlying Common Stock that have then vested under this Warrant that Holder has requested to be registered.  If Holder decides not to include all of its Underlying Common Stock in any registration statement filed by Company, Holder shall nevertheless continue to have the right to include any Underlying Common Stock that have then vested under this Warrant in any subsequent registration statement or registration

 

5

 

statements as may be filed by the Company with respect to the offering of its Common Stock or other securities under the Act, all upon the terms and conditions set forth herein.

 

In connection with any offering involving an underwriting of shares of the Company’s Common Stock in which Holder makes a written request pursuant to the provisions of the preceding paragraph, the Company shall not be required to include any of Holder’s Underlying Common Stock in such underwriting unless Holder accepts the terms of the underwriting as agreed upon between the Company and the underwriters selected by it, and then only in such quantity as the underwriters determine in their sole reasonable discretion will not jeopardize the success of the offering by the Company.  If the total amount of securities, including Holder’s Underlying Common Stock, requested to be included in such registration exceeds the amount of securities that the underwriters determine in their sole reasonable discretion is compatible with the success of the offering, then the Company will include in such registration, to the extent of the number which the Company is so advised can be sold in such offering, (i) first securities proposed by the Company to be sold for its own account, and (ii) second Underlying Common Stock of the Holder and securities of other selling security holders requested to be included in such registration pro-rata on the basis of the number of share of such securities so proposed to be sold and so requested to be included; provided, however, that the Holder shall have pro-rata rights of registration with all shares sought to be included by officers and directors of the Company as well as holders of ten percent (10%) or more of the Company’s Common Stock.

 

(j)            Notices.  All notices, payments, requests and demands and other communications required or permitted under this Warrant shall be deemed to have been duly given, delivered and made if in writing and if served either by personal delivery to the party for whom it is intended or by being deposited postage prepaid, certified or registered mail, return receipt requested, to the address shown below or such other address as may be designated in writing hereafter by such party:

 

	
If   to the Company:
    	
 
    	
AdCare   Health Systems, Inc.
   5057 Troy Road
   Springfield, Ohio 45502
   Attn: David A. Tenwick
    
	
 
    	
 
    	
 
    
	
If   to the Holder:
    	
 
    	
Boyd   P. Gentry
   84 Palisades Road
   Atlanta, GA 30309
    

 

(k)           Governing Law.  This Warrant shall be construed and enforced in accordance with and governed by the laws of the State of Ohio.

 

(l)            Further Assurances.  The parties agree to execute, acknowledge and deliver any and all such other documents and to take any and all such other actions as may, in the reasonable opinion of either of the parties hereto, be necessary or convenient to carry out more efficiently any or all of the purposes of this Warrant.

 

6

 

(m)          Severability.  Any provisions of this Warrant which shall be prohibited by law or otherwise held invalid shall be ineffective only to the extent of such prohibition or invalidity and shall not invalidate or otherwise render ineffective any or all of the remaining provisions of this Warrant.

 

(n)           Parties in Interest; Assignment.  This Warrant and the various rights and obligations arising hereunder shall be binding upon and shall inure to the benefit of the parties hereto and to each and all of their respective successors and assigns.

 

(o)           Warrants Transferable.  This Warrant and the rights granted to the Holder hereof are transferable, in whole or in part, upon execution and delivery of the Notice of Assignment attached hereto and surrender of this Warrant at the office of the Company.  Upon receipt of the duly executed Notice of Assignment, the Company shall execute and deliver, in the name of the designated transferee or transferees, one or more new Warrants representing the right to purchase a like aggregate number of shares of Common Stock subject to the terms hereof.

 

IN WITNESS WHEREOF, the Company has caused this instrument to be signed by its President, attested by its Secretary as of the 31st day of March 2011.

 

	
 
    	
ADCARE   HEALTH SYSTEMS, INC.
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Gary Wade
    
	
 
    	
 
    	
Gary   Wade, President
    
	
 
    	
 
    
	
 
    	
 
    
	
Attest:
    	
/s/   Carol Groeber
    	
 
    	
 
    
	
 
    	
Carol   Groeber, Corporate Secretary
    	
 
    	
 
    

 

7

 

PURCHASE FORM

 

The undersigned,                    pursuant to the provisions of this Warrant hereby elects to purchase            shares of Common Stock of AdCare Health Systems, Inc.

 

	
Dated:
    	
 
    	
 
    	
 
    
	
 
    	
Signature
    
	
 
    	
 
    
	
 
    	
Address:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    

 

 

NOTICE OF ASSIGNMENT

 

FOR VALUE RECEIVED, the undersigned registered Holder of the within Warrant hereby sells, assigns and transfers unto                                                                   , whose address is                                                                                                  all of the rights of the undersigned under the Warrant, with respect to shares of Common Stock (as defined therein) of AdCare Health Systems, Inc., and, if such shares of Common Stock shall not include all the shares of Common Stock issuable as provided in the Warrant, that a new Warrant of like tenor for the number of shares of Common Stock not being transferred hereunder be issued in the name of and delivered to the undersigned, and does hereby irrevocably constitute and appoint                                              attorney to register such transfer on the books of AdCare Health Systems, Inc. maintained for that purpose, with full power of substitution in the premises.

 

 

	
Date:
    	
 
    	
 
    	
By:
    	
 
    
	
 
    	
(Signature of Holder)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]